- A new Danish study indicates that semaglutide, marketed as Wegovy and Ozempic, may help individuals grappling with alcohol use disorder.
- The 26-week trial involved 108 obese patients with alcohol use disorder, with half receiving semaglutide and the other half a placebo, alongside talking therapy.
- Participants administered semaglutide showed a significant reduction in heavy drinking days, decreasing from an average of 17 to five per month, and a substantial drop in overall alcohol consumption.
- Researchers suggest that semaglutide influences the biological mechanisms underlying addiction, potentially offering a new complementary treatment approach for alcohol use disorder.
- Experts acknowledge the encouraging early findings but emphasise the necessity for larger, longer-term trials across diverse populations to confirm efficacy and understand long-term effects.
IN FULL
